The a-Gliatest® IgA is intended for the semi-quantitative determination of IgA antibodies directed against gliadin in human serum. The assay is an aid in the diagnosis of celiac disease and should be used in conjunction with other serological tests and clinical findings.

The a-Gliatest® IgG is intended for the semi-quantitative determination of IgG antibodies directed against gliadin in human serum. The assay is an aid in the diagnosis of celiac disease and should be used in conjunction with other serological tests and clinical findings.

The a-GliaPep® IgA is intended for the semi-quantitative determination of IgA antibodies directed against deamidated gliadin peptide in human serum. The assay is an aid in the diagnosis of celiac disease and should be used in conjunction with other serological tests and clinical findings.

The a-GliaPep® IgG is intended for the semi-quantitative determination of IgG antibodies directed against deamidated gliadin peptide in human serum. The assay is an aid in the diagnosis of celiac disease and should be used in conjunction with other serological tests and clinical findings.

Device Description

Each test kit for a-Gliatest® IgA, a-Gliatest® IgG, a-GliaPep® IgA, and a-GliaPep® IgG consists of one (1) microtiter plate (12 strips of 8 microwells coated with purified a-gliadin antigen or deamidated gliadin peptide antigen), assay controls (positive and negative), a ready-to-use set of five (5) calibrators, Horseradish Peroxidase (HRP) goat anti-human IgA or IgG conjugate, serum diluent, Tetramethylbenzidine (TMB) enzyme substrate, stop solution, and washing solution required for the assay.

AI/ML Overview

The provided document describes the Grifols USA, Inc. a-Gliatest® IgA, a-Gliatest® IgG, a-GliaPep® IgA, and a-GliaPep® IgG devices, which are intended for the semi-quantitative determination of IgA/IgG antibodies directed against gliadin or deamidated gliadin peptide in human serum as an aid in the diagnosis of celiac disease.

Here's an analysis of the acceptance criteria and the studies performed, based on the provided text:

1. Table of Acceptance Criteria and Reported Device Performance

The acceptance criteria are generally implied through comparison with a predicate device (Aeskulisa® Glia A/G (K052439)) and through performance metrics like precision, linearity, and detection limits. The method comparison and clinical studies aim to demonstrate substantial equivalence and adequate diagnostic performance.

Below is a summary of the reported performance for each device, with implied acceptance criteria based on the context of 'substantial equivalence' to the predicate and satisfactory clinical utility. The document does not explicitly state pre-defined acceptance criteria for the clinical or method comparison studies in terms of specific percentages, but rather presents the results. For analytical performance, the studies demonstrate what is considered acceptable.

Metric (Implied Acceptance Criteria)	α-Gliatest® IgA Performance	α-Gliatest® IgG Performance	α-GliaPep® IgA Performance	α-GliaPep® IgG Performance
Analytical Performance
Intra-assay Precision (CV%)	Range: 2.7-7.7%	Range: 2.4-5.4%	Range: 3.3-9.8%	Range: 3.6-7.1%
Inter-run Precision (CV%)	Range: 3.3-17.3%	Range: 1.6-16.9%	Range: 2.3-14.9%	Range: 2.2-9.6%
Inter-lot Precision (CV%)	Range: 0.9-10.1%	Range: 1.4-4.1%	Range: 2.1-8.1%	Range: 1.2-10.2%
Linearity Range (AU/mL)	1.1 - 100	2.5 - 99.4	1.1 - 100	1.1 - 100
Claimed Limit of Detection (LoD)	1.1 AU/mL	2.4 AU/mL	1.1 AU/mL	1.1 AU/mL
Method Comparison Study (vs. Predicate)
Positive Agreement	89.7% (95% C.I. 78.8%-96.1%)	78.8% (95% C.I. 67.0%-87.9%)	72.0% (95% C.I. 57.5%-83.8%)	79.4% (95% C.I. 67.3%-88.5%)
Negative Agreement	85.0% (95% C.I. 77.3%-90.9%)	88.6% (95% C.I. 82.0%-93.5%)	91.5% (95% C.I. 85.3%-95.7%)	88.4% (95% C.I. 81.9%-93.2%)
Overall Agreement	86.5% (95% C.I. 80.6%-91.2%)	85.4% (95% C.I. 79.6%-90.0%)	86.0% (95% C.I. 80.1%-90.8%)	85.6% (95% C.I. 79.9%-90.1%)
Clinical Study Performance
Sensitivity	69.3% (95% C.I. 60.1%-77.5%)	79.6% (95% C.I. 71.8%-86.0%)	79.6% (95% C.I. 69.9%-87.2%)	90.5% (95% C.I. 83.2%-95.3%)
Specificity	75.7% (95% C.I. 67.9%-82.3%)	88.5% (95% C.I. 82.2%-93.2%)	93.2% (95% C.I. 87.9%-96.7%)	85.1% (95% C.I. 78.4%-90.4%)

2. Sample Size Used for the Test Set and Data Provenance

α-Gliatest® IgA:
- Method Comparison Test Set: 178 clinical samples. Provenance: Includes clinically-diagnosed celiac positive (clinical history and/or biopsy) and negative samples (healthy blood donors, IBD, IBS, food intolerances, autoimmune disorders, infectious diseases, Type 1 diabetes patients). Retrospective.
- Clinical Study Test Set: 262 clinical samples (114 celiac positive, 148 negative from disease controls). Provenance: Celiac patient samples diagnosed with clinical findings and/or confirmed with biopsy. Negative samples from disease control patients (autoimmune disorders, infectious diseases, IBD, IBS, Type 1 diabetes). Also, 196 healthy blood donor samples. Retrospective.
α-Gliatest® IgG:
- Method Comparison Test Set: 198 clinical samples (51 celiac positive, including 10 IgA-deficient celiac patients; negative samples from healthy blood donors, IBD, IBS, food intolerances, autoimmune disorders, infectious diseases, Type 1 diabetes patients). Retrospective.
- Clinical Study Test Set: 285 clinical samples (127 celiac positive, 10 IgA-deficient celiac patients; 148 negative from disease controls). Provenance: Celiac patient samples diagnosed with clinical findings and confirmed with biopsy. Negative samples from disease control patients (autoimmune disorders, infectious diseases, IBD, IBS, Type 1 diabetes). Also, 196 healthy blood donor samples. Retrospective.
α-GliaPep® IgA:
- Method Comparison Test Set: 179 clinical samples. Provenance: Clinically-diagnosed celiac positive (clinical history and/or biopsy) and negative samples (healthy blood donors, IBD, IBS, food intolerances, autoimmune disorders, infectious diseases, Type 1 diabetes patients). Retrospective. The samples were within the linearity range of the assay.
- Clinical Study Test Set: 241 clinical samples (93 celiac positive, 148 negative from disease controls). Provenance: Celiac patient samples diagnosed with clinical findings and confirmed with biopsy. Negative samples from disease control patients (autoimmune disorders, infectious diseases, IBD, IBS, Type 1 diabetes). Also, 145 healthy blood donor samples. Retrospective.
α-GliaPep® IgG:
- Method Comparison Test Set: 201 clinical samples (57 celiac positive, including 10 IgA-deficient celiac patients; 146 negative samples recruited similarly to other assays). Provenance: Clinically-diagnosed celiac positive (clinical history and/or biopsy) and negative samples (healthy blood donors, IBD, IBS, food intolerances, autoimmune disorders, infectious diseases, Type 1 diabetes patients). Retrospective. The samples were within the linearity range of the assay.
- Clinical Study Test Set: 253 clinical samples (95 celiac positive, including 10 IgA-deficient celiac patients; 148 negative from disease controls). Provenance: Celiac patient samples diagnosed with clinical findings (31.6%) and confirmed with biopsy (68.4%). Negative samples from disease control patients (autoimmune disorders, infectious diseases, IBD, IBS, Type 1 diabetes). Also, 145 healthy blood donor samples. Retrospective.

For all studies, data provenance is global/not specified, and the data is retrospective.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Their Qualifications

The document does not explicitly state the number of experts or their specific qualifications (e.g., radiologist with X years of experience) used to establish the ground truth for the test sets. It mentions that celiac positive samples were "clinically-diagnosed celiac positive (clinical history and/or biopsy)" and "diagnosed with clinical findings and confirmed with biopsy." This implies that the ground truth was established by medical professionals, likely gastroenterologists or pathologists, based on established diagnostic criteria for celiac disease, including clinical presentation and histological findings from biopsy. However, the specific number and formal qualifications of these experts are not provided.

4. Adjudication Method for the Test Set

The document does not describe a formal adjudication method (e.g., 2+1, 3+1) for resolving discrepancies in ground truth determination or in the interpretation of clinical findings and biopsies for the test set. The ground truth seems to be implicitly accepted based on the "clinical findings and/or biopsy" diagnosis.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done, and the Effect Size of Human Readers Improve with AI vs. Without AI Assistance

No, a Multi-Reader Multi-Case (MRMC) comparative effectiveness study was not done. These devices are in vitro diagnostic (IVD) assays, not imaging interpretation algorithms where human readers would typically be involved in interpreting results. The studies compare the performance of the device itself to a predicate device or to clinical ground truth, not to human reader performance with or without AI assistance.

6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done

Yes, the studies conducted are standalone performance evaluations of the assay devices. The "method comparison studies" and "clinical studies" evaluate the performance of each assay (α-Gliatest® IgA, α-Gliatest® IgG, α-GliaPep® IgA, α-GliaPep® IgG) in isolation, comparing its output to a predicate device's output or to the clinical ground truth. There is no human-in-the-loop component described for the operation or interpretation of these assays beyond standard laboratory procedures.

7. The Type of Ground Truth Used

The ground truth for celiac positive samples was established based on:

Clinical findings: Clinical history and presentation consistent with celiac disease.
Biopsy: Histological confirmation from intestinal biopsy, which is a gold standard for celiac disease diagnosis.

For negative samples, the ground truth was based on:

Healthy blood donors.
Patients with other relevant conditions (IBD, IBS, autoimmune disorders, infectious diseases, Type 1 diabetes) who would not be expected to have celiac disease.

This can be categorized as a combination of expert consensus (clinical findings) and pathology (biopsy).

8. The Sample Size for the Training Set

The document primarily describes validation studies (test sets) and does not explicitly mention a separate "training set" for the development of these IVD assays. IVD products are typically developed through iterative processes of antigen/antibody selection and optimization, with assay parameters being refined, but these development phases are not usually referred to as "training sets" in the same way machine learning models are. The calibrators and controls are formulated from pooled sera, and new lots are calibrated against original calibrators, which involves testing (effectively a form of internal "training" or standardization) against:

Original calibrators
Normal human sera
Clinical samples
Internal standards

However, a specific "training set" size for algorithm development (as would be typical for AI/ML devices) is not applicable or stated for this type of immunoassay.

9. How the Ground Truth for the Training Set Was Established

As noted above, a distinct "training set" for an algorithm in the AI/ML sense is not applicable to these IVD assays. Instead, the assay's operational parameters (like calibrator values) are established using:

Pooled sera with known anti-gliadin antibody levels from celiac patients.
Normal human sera.
Clinical samples.
Internal standards.

The ground truth for these calibrators and controls would stem from the clinical diagnoses (clinical findings and/or biopsy) of the patient populations from which the sera were obtained. The document states, "Calibrators are dilutions of pooled sera with anti-gliadin antibody from patients with celiac disease." This implies that the ground truth for these pooled sera was established through the diagnosis of celiac disease in the donor patients.

Summary

{0}------------------------------------------------

K113377

Grifols USA, Inc.
2410 Lillyvale Avenue
Los Angeles, CA
90032-3548
Tel. (323) 225-2221
(800) 421-0008
www.grifols.com

Page 1 of 17

510(k) Summary

DEC 1 4 2012

Date 510(k) Summary Prepared: 12 December 2012

1. 510(k) Owner: Grifols USA, LLC
1. Submitter: Grifols USA, LLC

Submitter Name: Grifols USA, LLC. Contact Person: Catherine L. Wong Address: 2410 Lillyvale Avenue Los Angeles, CA 90032-3514 (323) 227-7280 Telephone: Fax No .: (323) 441-7902

Device Information 4.
Proprietary and Established Names:

a-Gliatest® IgA, a-Gliatest®IgG, a-GliaPep® IgA, and a-GliaPep®IgG

Common Names:

Gliadin IgA and Gliadin IgG

1. Regulatory Information:
  Regulation No .: 21 CFR § 866.5750 Radioallergosorbent (RAST) immunological test system Regulation Section: Classification: Class 2 : Product Code: MST, Antibodies, Gliadin Panel: Immunology
Predicate Devices: 6.
Aeskulisa® Glia A (K052439), predicate for a-Gliatest® IgA and a-GliaPep® IgA Aeskulisa® Glia G (K052439), predicate for a-Gliatest® IgG and a-GliaPep® IgG

{1}------------------------------------------------

7. Device Description

8. Intended Use

Intended Use for a-Gliatest® IgA: .

The a-Gliatest® IgA is intended for the semi-quantitative determination of IgA antibodies directed against gliadin in human serum. The assay is an aid in the diagnosis of celiac disease and should be used in conjunction with other serological tests and clinical findings.

Intended Use for a-Gliatest® IgG:

Intended Use for a-GliaPep® IgA: .

The a-GliaPep® IgA is intended for the semi-quantitative determination of IgA antibodies directed against deamidated gliadin peptide in human serum. The assay is an aid in the diagnosis of celiac disease and should be used in conjunction with other serological tests and clinical findings.

Intended Use for a-GliaPep® IgG:

{2}------------------------------------------------

Summary of Comparison with Predicate Device 9.

The devices, a-Gliatest® IgA, a-Gliatest® IgG, a-GliaPep® IgA, and a-GliaPep® IgG, have been compared with their predicate devices (Aeskulisa ) Glia A and Aeskulisa® · Glia G, K052439), and found to be substantially equivalent.

The design, features, technological characteristics, specifications and performance of the devices have been compared with those of the predicate devices, as shown in Tables 1, 2, 3 and 4.

No.	Item	α-Gliatest® IgA	α-GliaPep® IgA	PredicateAESKULISA® Glia-A(K052439)
1.	Intended Use	The α-Gliatest® IgA isintended for thesemi-quantitativedetermination of IgAantibodies directed againstgliadin in human serum. Theassay is an aid in thediagnosis of celiac diseaseand should be used inconjunction with otherserological tests and clinicalfindings.	The α-GliaPep® IgA isintended for thesemi-quantitativedetermination of IgAantibodies directed againstdeamidated gliadin peptidein human serum. The assayis an aid in the diagnosis ofceliac disease and should beused in conjunction withother serological tests andclinical findings.	The AESKULISA Glia-A isa solid phase enzymeimmunoassay for thesemi-quantitative andqualitative detection of IgAantibodies against gliadin inhuman serum. The assay isan aid in the diagnosis ofceliac disease(gluten-sensitiveenteropathy) and should beused in conjunction withother serological tests andclinical findings.
2.	Methodology	ELISA	Same	Same
3.	Analyte	IgA antibodies againstgliadin in human serum	IgA antibodies againstdeamidated gliadin peptidein human serum	IgA antibodies againstgliadin in human serum
4.	Enzyme-Conjugate	Horseradish peroxidase	Same	Same
5.	Substrate/Chromogen	TMB	Same	Same
6.	OD Reading	450 nm	Same	Same
7.	PositiveControl	Human serum	Same	Same
8.	NegativeControl	Human serum	Same	Same
9.	Storage	2-8°C	Same	Same
10.	Patient SampleDilution	1:101	Same	Same
11.	Patient SampleVolumeRequired	100 µL	Same	Same

Table 1 Device Similarities Between a-Gliatest® IgA, a-GliaPep® IgA and Predicate (Aeskulisa® Glia A, K052439)

{3}------------------------------------------------

No. Item	α-Gliatest® IgA	α-GliaPep® IgA	PredicateAESKULISA® Glia-A (K052439)
1.	CaptureAntigen	Purified α-gliadinantigen	Deamidated gliadin peptide	Purified α-gliadin antigen
2.	Controls	Positive, NegativeControls	Positive, Negative Controls	Positive, Negative, and Cut-offControls
3.	Calibrators	5 Levels: 0, 10, 20,50, 100 AU/mL	5 Levels: 0, 10, 20, 50, 100AU/mL	6 Levels: 0, 3, 10, 30, 100, 300U/mL
4.	Cut-off	8 AU/mL	8 AU/mL	15 AU/mL
5.	IncubationTimes	45-30-15 minutes	45-30-15 minutes	GLIA-A and GLIA-G(REF 7501US and REF7502US, respectively):30-15-15 minutesGLIA-A and GLIA-G(REF 7501US and REF7502US, respectively):30-30-30 minutes
6.	SampleDiluent	Ready-to-use	Ready-to-use	5X concentrate
7.	WashSolution/Buffer	20X concentrated	20X concentrated	50X concentrated
8.	LinearityRange	1.1 - 100 AU/mL	1.1 - 100 AU/mL	7.4 - 102.5 U/mL
9.	ClaimedLimit ofDetection	1.1 AU/mL	1.1 AU/mL	1.0 U/mL

Table 2 Device Differences Between a-Gliatest® IgA, a-GliaPep® IgA and Predicate (Aeskulisa® Glia A, K052439)

Table 3 Device Similarities Between a-Gliatest® IgG, a-GliaPep® IgG and Predicate (Aeskulisa® Glia A, K052439

No.	Item	α-Gliatest® IgG	α-GliaPep® IgG	PredicateAESKULISA® Glia-G(K052439)
1.	Intended Use	The α-Gliatest® IgG isintended for thesemi-quantitativedetermination of IgGantibodies directed againstgliadin in human serum. Theassay is an aid in thediagnosis of celiac diseaseand should be used inconjunction with otherserological tests and clinicalfindings.	The α-GliaPep® IgG isintended for thesemi-quantitativedetermination of IgGantibodies directed againstdeamidated gliadin peptidein human serum. The assayis an aid in the diagnosis ofceliac disease and should beused in conjunction withother serological tests andclinical findings.	The AESKULISA® Glia-Gis a solid phase enzymeimmunoassay for thesemi-quantitative andqualitative detection of IgGantibodies against gliadin inhuman serum. The assay isan aid in the diagnosis ofceliac disease (gluten-sensitive enteropathy) andshould be used inconjunction with otherserological tests and clinicalfindings.
2.	Methodology	ELISA	Same	Same
3.	Analyte	IgG antibodies againstgliadin in human serum	IgG antibodies againstdeamidated gliadin peptidein human serum	IgA antibodies againstgliadin in human serum

{4}------------------------------------------------

	No. Item	a-Gliatest® IgG	a-GliaPep® IgG	PredicateAESKULISA® Glia-G(K052439)
র্ব -	Enzyme-Conjugate	Horseradish peroxidase	Same	Same
5.	Substrate/Chromogen	TMB	Same	Same
6.	OD Reading	450 nm	Same	Same
7.	PositiveControl	Human serum	Same	Same
8.	NegativeControl	Human serum	Same	Same
ರ	Storage	2-8°C	Same	Same
10.	Patient Sample 1:101Dilution		Same	Same
11.	Patient Sample 100 uLVolumeRequired		Same	Same

Table 4 Device Differences Between α-Gliatest® IgG, α-GliaPep® IgG and Predicate

(Aeskulisa® Glia A, K052439)
Marketer Clian Cara Cases Cara Cara Cara Cara Cara Cara Cara Car

No.	Item	α-Gliatest® IgG	α-GliaPep® IgG	PredicateAESKULISA® Glia-G (K052439)
1.	CaptureAntigen	Purified α-gliadinantigen	Deamidated gliadin peptide	Purified α-gliadin antigen
2.	Controls	Positive, NegativeControls	Positive, Negative Controls	Positive, Negative, and Cut-offControls
3.	Calibrators	5 Levels: 2, 10, 20,50, 100 AU/mL	5 Levels: 0, 10, 20, 50, 100AU/mL	6 Levels: 0, 3, 10, 30, 100, 300U/mL
4.	Cut-off	50 Au/mL	10 AU/mL	15 AU/mL
5.	IncubationTimes	45-30-15 minutes	45-30-15 minutes	Glia-A and Glia-G(REF 7501US and REF7502US, respectively):30-15-15 minutes
				Glia-A and GLIA-G(REF 7501US and REF7502US, respectively):30-30-30 minutes
6.	SampleDiluent	Ready-to-use	Ready-to-use	5X concentrated
7.	WashSolution/Buffer	20X concentrated	20X concentrated	50X concentrated
8.	LinearityRange	2.5 - 99.4 AU/mL	1.1 - 100 AU/mL	12.4 - 117.6 U/mL
9.	ClaimedLimit ofDetection	2.4 AU/mL	1.1 AU/mL	1.0 U/mL

{5}------------------------------------------------

Standard/Guidance Document Referenced 10.

The following standards were referenced in the submission:

CLSI EP5-A2, "Evaluation of Precision Performance of Quantitative Measurement . Methods"
CLSI EP6-A, "Evaluation of the Linearity of Quantitative Measurement . Procedures; A Statistical Approach"
CLSI EP7-A2, "Interference Testing in Clinical Chemistry" .
CLSI EP17-A, "Protocols for Determination of Limits of Detection and Limits of . Quantitation"
CLSI C28-A2, "How to Define and Determine Reference Intervals in the Clinical . Laboratory"
CLSI EP9-A2, "Method Comparison and Bias Estimation Using Patient Samples" .

11. Performance Characteristics

11.1 Analytical Performance

11.1.1 Precision Study

The intra-assay precision studies were each performed in one (1) assay run. Results are summarized in Tables 5 - 8.

Sample No.	1	2	3	4	5	6	7	8
Mean (AU/mL)	98.0	73.7	68.7	17.9	8.8	3.0	3.0	1.9
SD	3.50	2.62	2.08	0.49	0.30	0.20	0.08	0.15
CV%	3.6	3.6	3.0	2.7	3.5	6.8	2.7	7.7

Table 5 Intra-assay Precision Results for a-Gliatest® IgA

Table 6 Intra-assay Precision Results for a-Gliatest® IgG

Sample No.	1	2	3	4	5	6	7	8
Mean (AU/mL)	99.6	80.4	75.0	61.9	60.6	24.3	10.0	5.1
SD	2.38	3.35	2.53	2.35	2.39	0.86	0.36	0.28
CV%	2.4	4.2	3.4	3.8	3.9	3.6	3.6	5.4

Table 7 Intra-assay Precision Results for a-GliaPep® IgA

Sample No.	1	2	3	4	5	6	7	8
Mean (AU/mL)	98.2	86.6	65.8	17.8	9.7	4.4	2.7	1.8
SD	6.61	2.83	4.43	0.95	0.94	0.25	0.19	0.15
CV%	6.7	3.3	6.7	5.3	9.8	5.7	7.0	8.6

{6}------------------------------------------------

Sample No.	1	2	3	4	5	6	7	8
Mean (AU/mL)	97.5	55.6	24.5	15.1	10.4	8.1	6.2	4.0
SD	5.69	2.73	1.29	0.95	0.62	0.30	0.44	0.19
CV%	5.8	4.9	5.3	6.3	5.9	3.6	7.1	4.7

Table 8 Intra-assay Precision Results for a-GliaPep® IgG

The inter-run (between days) precision study results are summarized in Tables 9 -12.

Table 9 Inter-run Precision Results for a-Gliatest® IgA

Sample No.	1	2	3	4	5	6	7	8
Mean (AU/mL)	95.9	77.8	69.0	17.8	9.0	3.3	3.1	1.9
SD	3.15	7.68	3.94	0.82	1.30	0.24	0.26	0.33
CV%	3.3	9.9	5.7	4.6	14.4	7.2	8.3	17.3

Table 10 Inter-run Precision Results for a-Gliatest® IgG

Sample No.	1	2	3	4	5	6	7	8
Mean (AU/mL)	97.9	82.4	75.5	64.4	60.2	26.1	10.6	5.8
SD	1.53	2.48	2.62	2.12	4.73	2.76	0.46	0.99
CV%	1.6	3.0	3.5	3.3	7.9	11.0	4.3	16.9

Table 11 Inter-run Precision Results for a-GliaPep 9 IgA

Sample No.	1	2	3	4	5	6	7	8
Mean (AU/mL)	96.6	84.4	61.1	18.1	9.6	3.8	2.8	1.5
SD	2.19	4.97	4.50	2.24	0.81	0.54	0.20	0.22
CV%	2.3	5.9	7.4	12.4	8.4	14.2	7.2	14.9

Table 12 Inter-run Precision Results for a-GliaPep® IgG

Sample No.	1	2	3	4	5	6	7	8
Mean (AU/mL)	97.5	49.3	25.4	15.9	10.0	7.9	5.9	4.1
SD	2.17	4.39	2.44	1.30	0.81	0.33	0.29	0.39
CV%	2.2	8.9	9.6	8.2	8.1	4.2	4.9	9.4

The inter-lot precision study results are summarized in Tables 13-16.

Table 13 Inter-lot Precision Results for a-Gliatest® IgA

Serum Sample No.	1	2	3	4	5
Mean (AU/mL)	87.3	42.8	22.7	11.6	7.1
S.D.	0.81	2.46	1.22	1.18	0.28
C.V. (%)	0.9	5.8	5.4	10.1	3.9

{7}------------------------------------------------

Serum Sample No.	1	2	3	4	5
Mean (AU/mL)	84.9	50.3	42.7	24.4	11.1
S.D.	2.13	1.07	0.72	1.01	0.15
C.V. (%)	2.5	2.1	1.7	4.1	1.4

Table 14 Inter-lot Precision Results for a-Gliatest® IgG

Table 15 Inter-lot Precision Results for a-GliaPep® IgA

Serum Sample No.	1	2	3	4	5
Mean (AU/mL)	85.4	42.6	22.6	14.3	7.3
S.D.	1.79	1.86	1.83	0.50	0.38
C.V. (%)	2.1	4.4	8.1	3.5	5.1

Table 16 Inter-lot Precision Results for a-GliaPep® IgG

Serum Sample No.	1	2	3	4	5
Mean (AU/mL)	83.1	45.6	26.3	13.1	4.1
S.D.	0.99	1.31	0.39	1.34	0.12
C.V. (%)	1.2	2.9	1.5	10.2	3.0

11.1.2 Linearity/Assay Reportable Range

Linearity was studied using four (4) positive serum samples each for the a-Gliatest® IgA, a-Gliatest® IgG, a-GliaPep® IgA, and a-GliaPep® IgG. Each sample was diluted with a low concentration serum sample at around the limit of detection (LoD), 1.1 AU/mL for a-Gliatest® IgA, 2.4 AU/mL for a-Gliatest® IgG, 1.1 AU/mL for a-GliaPep® IgA , and 1.1 AU/mL for a-GliaPep® IgG, respectively, using a dilution scheme.

The results of one (1) representative sample for a-Gliatest® IgA show a slope of 1.017 (95% C.I. 0.991 to 1.044), Y-intercept of -1.637 (95% C.I. -3.210 to -0.064) and R2 of 0.9988. The results of one (1) representative sample for a-Gliatest® IgG show a slope of 0.997 (95% C.I. 0.931 to 1.064), Y-intercept of 1.857 (95% C.I. -2.182 to 5.896) and R2 of 0.9924. The results of one (1) representative sample for a-GliaPep® IgA show a slope of 1.018 (95% C.I. 0.994 to 1.042), Y-intercept of -1.697 (95% C.I. -3.075 to 0.320) and R2 of 0.9990. The results of one (1) representative sample for a-Gliatest® IgG show a slope of 1.014 (95% C.I. 0.987 to 1.041), Y-intercept of -1.705 (95% C.I. -3.354 to -0.056) and R2 of 0.9988.

{8}------------------------------------------------

The results of the study support the linear range and the claimed assay range of 1.1-100 AU/mL for a-Gliatest® IgA, 2.5-99.4 AU/mL for a-Gliatest® IgG, 1.1-100 AU/mL for a-GliaPep® IgA, and 1.1-100 AU/mL for α-GliaPep® IgG.

11.1.3 Traceability, Stability and Expected Values (Controls and Calibrators)

Traceability

Calibrators are not traceable to any recognized standards. Calibrators are dilutions of pooled sera with anti-gliadin antibody from patients with celiac disease. The new calibrator and control lots are formulated from an array of anti-gliadin antibody positive sera obtained from various commercial plasma centers stored at -70°C. The calibrators and controls are taken from different pooled sera. As new lots of calibrators are developed, studies are performed to calibrate values against original calibrators. Each lot of calibrator is also tested in comparison with normal human sera, clinical samples and internal standards. The concentration values of the calibrators are as follows:

Calibrator	α-Gliatest® IgA	α-Gliatest® IgG
Cal S5	100 AU/mL	100 AU/mL
Cal S4	50 AU/mL	50 AU/mL
Cal S3	20 AU/mL	20 AU/mL
Cal S2	10 AU/mL	10 AU/mL
Cal S1	0 AU/mL	2 AU/mL

Calibrator	α-GliaPep® IgA	α-GliaPep® IgG
Cal S5	100 AU/mL	100 AU/mL
Cal S4	50 AU/mL	50 AU/mL
Cal S3	20 AU/mL	20 AU/mL
Cal S2	10 AU/mL	10 AU/mL
Cal S1	0 AU/mL	0 AU/mL

Kit Stability .

Stability studies support the expiration date claims of 12 months at 2-8°C for the α-Gliatest® IgA, α-Gliatest® IgG, α -GliaPep® IgA, and a-GliaPep® IgG.

{9}------------------------------------------------

. Sample Stability

Specimens should be stored at 2-8°C for no longer than five (5) days. For longer storage, serum specimens should be frozen at -20°C. Repeated freezing and thawing of samples should be avoided.

11.1.4 Detection Limit

The limits of blank (LoB) and the claimed limits of detection (LoD) for a-Gliatest® IgA, a-Gliatest® IgG, a-GliaPep® IgA and a-GliaPep® IgG, are shown in Table 17.

	LoB (AU/mL)	Claimed LoD(AU/mL)
α-Gliatest® IgA	0.59	1.1
α-Gliatest® IgG	1.66	2.4
α-GliaPep® IgA	0.13	1.1
α-GliaPep® IgG	0.18	1.1

Table 17 Limits of Blank and Claimed Limits of Detection for «-Gliatest® IgA & IgG and a-GliaPep® IgA & IgG

Analytical Specificity 11.1.5

Cross-reactivity studies were performed for a-Gliatest® IgA, a-Gliatest® IgG, a-GliaPep® IgA, and a-GliaPep® IgG, using 148 characterized clinical samples from individuals with autoimmune disorders, such as Hashimoto's Thyroiditis (HT), Graves' Disease (GD), Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), Sjogren's, Systemic Sclerosis and Autoimmune Hepatitis (AH); patients with Inflammatory Bowel Disease (IBD), including Crohn's Disease and Ulcerative Colitis (UC); Irritable Bowel Syndrome (IBS), Type 1 Diabetes and H. pylori infection.

One (1) RA, 11 SLE, seven (7) HT, six (6) GD, one (1) AH, one (1) Crohn's Disease, five (5) IBS, and four (4) Type 1 Diabetes out of 148 samples (36/148, 24.3%) were tested positive for a-Gliatest IgA. One (1) RA, two (2) SLE, one (1) GD, one (1) Sjogren's, two (2) Crohn's Disease, two (2) UC, five (5) IBS, and three (3) Type 1 Diabetes out of 148 samples (17/148, 11.5%) were tested positive for a-Gliatest IgG.

Four (4) HT, one (1) GD, one (1) AH, two (2) IBS, one (1) Type 1 Diabetes, and one (1) H. pylori out of 148 samples (10/148, 6.8%) were

{10}------------------------------------------------

tested positive for a-GliaPep IgA. Two (2) RA, two (2) SLE, three (3) HT, four (4) GD, one (1) AH, two (2) Crohn's Disease, one (1) UC, two (2) IBS, two (2) Type 1 Diabetes, and three (3) H. pylori out of 148 samples (22/148, 14.9%) were tested positive for a-GliaPep IgG.

Interference was studied by mixing the serum samples with known anti-gliadin antibody levels with the potentially interfering substances.

The study results demonstrated that hemoglobin (up to 2 g/L), . bilirubin (up to 342 umol/L), rheumatoid factor (up to 100 IU/mL) or lipids (triglycerides up to 1.08 mmol/L) does not significantly interfere with the performance of the a-Gliatest IgA.
The study results demonstrated that hemoglobin (up to 2 g/L), ● bilirubin (up to 256 umol/L), rheumatoid factor (up to 100 IU/mL) or lipids (triglycerides up to 1.08 mmol/L) does not significantly interfere with the performance of the a-Gliatest IgG.
� The study results demonstrated that hemoglobin (up to 1.5 g/L), bilirubin (up to 256 umol/L), theumatoid factor (up to 100 IU/mL) or lipids (triglycerides up to 1.08 mmol/L) does not significantly interfere with the performance of the a-GliaPep IgA.
The study results demonstrated that hemoglobin (up to 1.5 g/L), bilirubin (up to 342 umol/L), rheumatoid factor (up to 100 IU/mL) or lipids (triglycerides up to 1.47 mmol/L) does not significantly interfere with the performance of the α-GliaPep IgG.

11.1.6 Assay Cut-off

The normal range of each assay was established by testing over 160 serum samples from healthy subjects and non-celiac controls, such as Inflammatory Bowel Disease (IBD) patients, on each assay.

The assay cut-off value for a-Gliatest® IgA was determined as follows: <8 AU/mL Negative ≥8 AU/mL Positive

{11}------------------------------------------------

The assay cut-off value for a-Gliatest® IgG was determined as follows: <50 AU/mL Negative ≥5() AU/mL Positive

The assay cut-off value for α-GliaPep® IgA was determined as follows: <8 AU/mL Negative Positive ≥8 AU/mL

The assay cut-off value for a-GliaPep® IgG was determined as follows: <10 AU/mL Negative ≥10 AU/mL Positive

11.2 Method Comparison Studies

a-Gliatest® IgA 11.2.1

A method comparison study was performed which compared the a-Gliatest® IgA to a comparator test using 178 clinical samples. These samples consist of clinically-diagnosed celiac positive (clinical history and/or biospy) and negative samples. The negative samples were obtained from healthy blood donors, inflammatory bowel disease (IBD) patients, irritable bowel syndrome (IBS) patients, patients affected by food intolerances, patients with autoimmune disorders, patients with infectious diseases and patients with Type 1 diabetes. All samples were tested using a-Gliatest® IgA and the comparator test kit. The results of the studies are summarized in Table 18.

				Table 18 Results of Method Comparison Study for a-Gliatest IgA
--	--	--	--	----------------------------------------------------------------	--	--	--

		Aeskulisa Glia A (K052439)(Cut-off = 15 AU/mL)
		Positive	Negative	Total
α-Gliatest® IgA(Cut-off 8 AU/mL)	Positive	52	18	70
	Negative	6	102	108
	Total	58	120	178

Positive Agreement = 89.7% (95% C.I. 78.8% - 96.1%) Negative Agreement = 85.0% (95% C.I. 77.3% - 90.9%) Overall Agreement = 86.5% (95% C.I. 80.6% - 91.2%)

C.I. = Confidence Interval

{12}------------------------------------------------

a-Gliatest® IgG 11.2.2

A method comparison study was performed which compared the a-Gliatest® IgG to a comparator test using 198 clinical samples. These samples consist of 51 clinically-diagnosed celiac positive (clinical history and/or biospy), which include 10 total IgA-deficient celiac patients, and negative samples. The negative samples were obtained from healthy blood donors, inflammatory bowel disease (IBD) patients, irritable bowel syndrome (IBS) patients, patients affected by food intolerances, patients with autoimmune disorders, patients with infectious diseases and patients with Type 1 diabetes. All samples were tested using the a-Gliatest® IgG and the comparator test kit. The results of the studies are summarized in Table 19.

Table 19 Results of Method Comparison Study for a-Gliatest® IgG

		Aeskulisa® Glia G (K052439)(Cut-off = 15 AU/mL)
		Positive	Negative	Total
α-Gliatest® IgG(Cut-off 50 AU/mL)	Positive	52	15	67
	Negative	14	117	131
	Total	66	132	198

Positive Agreement = 78.8% (95% C.I. 67.0% - 87.9%) Negative Agreement = 88.6 % (95% C.I. 82.0% - 93.5%) Overall Agreement = 85.4% (95% C.I. 79.6% - 90.0%)

α-GliaPep® IgA 11.2.3

A method comparison study was performed which compared the a-GliaPep® IgA to a comparator test using 179 clinical samples within the linearity range of the assay. These samples consist of clinically-diagnosed celiac positive (clinical history and/or biospy) and negative samples. The negative samples were obtained from healthy blood donors, IBD patients, IBS patients, patients affected by food intolerances, patients with autoimmune disorders, patients with infectious diseases and patients with Type 1 diabetes. All samples were tested using a-GliaPep® IgA and the comparator test kit. The results of the studies are summarized in Table 20.

{13}------------------------------------------------

		Aeskulisa® Glia A (K052439)(Cut-off = 15 AU/mL)
		Positive	Negative	Total
α-GliaPep® IgA(Cut-off 8 AU/mL)	Positive	36	11	47
	Negative	14	118	132
	Total	50	129	179

Table 20 Results of Method Comparison Study for α-GliaPep® IgA

Positive % Agreement = 72.0% (95% C.I. 57.5% - 83.8%) Negative % Agreement = 91.5% (95% C.I. 85.3% - 95.7%) Overall % Agreement = 86.0% (95% C.I. 80.1% - 90.8%)

a-GliaPep® IgG 11.2.4

The a-GliaPep® IgG test was tested in comparison to the predicate, using 201 clinical samples within the linearity range of the assay. These samples consist of 57 clinically-diagnosed celiac positive (clinical history and/or biospy), which include 10 total IgA-deficient celiac patients, and 146 negative samples. The negative samples were ontained from healthy blood donors, IBD patients, IBS patients, patients affected by food intolerances, patients with autoimmune disorders, patients with infectious diseases and patients with Type 1 diabetes. All samples were tested using the a-GliaPep® IgG and the comparator test kit. The results of the studies are summarized in Table 21.

Aeskulisa® Glia G (K052439)(Cut-off = 15 AU/mL)
	Positive	Negative	Total
α-GliaPep® IgG(Cut-off 10 AU/mL)	Positive	50	16	66
	Negative	13	122	135
	Total	63	138	201

Table 21 Results of Method Comparison Study for a-GliaPep® IgG

Positive % Agreement = 79.4% (95% C.I. 67.3% - 88.5%) Negative % Agreement = 88.4% (95% C.I. 81.9% - 93.2%) Overall % Agreement = 85.6% (95% C.I. 79.9% - 90.1%)

{14}------------------------------------------------

11.3 Clinical Studies

α-Gliatest® IgA 11.3.1

For the a-Gliatest® IgA, the clinical study included 262 clinical samples, of which 114 are positive celiac patients and 148 are negative samples from disease control patients with autoimmune disorders, infectious diseases, IBD, IBS and Type 1 diabetes. The celiac patient samples were diagnosed with clinical findings and/or confirmed with biopsy. Table 22 demonstrates the clincal performance of the a-Gliatest® IgA.

		Celiac Disease
		Positive	Negative	Total
a-Gliatest® IgA(Cut-off 8 AU/mL)	Positive	79	36	115
	Negative	35	112	147
	Total	114	148	262

Table 22 Clinical Study Results of a-Gliatest® IgA

Specificity = 75.7% (95% C.I. 67.9% - 82.3%)

For the a-Gliatest IgA assay, 196 healthy blood donor samples were also tested, of which six samples (3.1%) tested positive.

a-Gliatest® IgG 11.3.2

For the a-Gliatest® IgG, the clinical study included 285 clinical samples, of which 127 are positive celiac patients, 10 are total IgA-deficient celiac patients and 148 are negative samples from disease control patients with autoimmune disorders, infectious diseases, IBD, IBS and Type 1 diabetes. The positive celiac patient samples were diagnosed with clinical findings and confirmed with biopsy. Table 23 demonstrates the clinical performance of the a-Gliatest® IgG assay.

Table 23 Clinical Study Results of a-Gliatest® IgG

		Celiac Disease
		Positive	Negative	Total
α-Gliatest® IgG(Cut-off 50 AU/mL)	Positive	109	17	126
	Negative	28	131	159
	Total	137	148	285

Sensitivity = 79.6% (95% C.I. 71.8% - 86.0%)

Specificity = 88.5% (95% C.I. 82.2% - 93.2%)

For the a-Gliatest IgG assay, 196 healthy blood donor samples were also tested, of which 10 samples (5.1%) tested positive.

{15}------------------------------------------------

α-GliaPep® IgA 11.3.3

For the a-GliaPep® IgA, the clinical study included 241 clinical samples, of which 93 are positive celiac patients and 148 are negative samples from disease control patients with autoimmune disorders, infectious diseases, IBD, IBS and Type 1 diabetes. The celiac patient samples were diagnosed with clinical findings and confirmed with biopsy. Table 24 demonstrates the clincal performance of the a-GliaPep® IgA.

		Celiac Disease
		Positive	Negative	Total
α-Gliapep® IgA(Cut-off 8 AU/mL)	Positive	74	10	84
	Negative	19	138	157
	Total	93	148	241

Table 24 Clinical Study Results of a-GliaPep® IgA

Sensitivity = 79.6% (95% C.I. 69.9% - 87.2%) Specificity = 93.2% (95% C.I. 87.9% - 96.7%)

For the a-GliaPep IgA assay, 145 healthy blood donor samples were also tested, of which five samples (3.5%) tested positive.

a-GliaPep® IgG 11.3.4

For the a-GliaPep® IgG, the clinical study included 253 clinical samples, of which 95 are positive celiac patients, 10 are total IgA-deficient celiac patients and 148 are negative samples from disease control patients with autoimmune disorders, infectious diseases, IBD, IBS and Type 1 diabetes patient samples. The positive celiac patient samples were diagnosed with clinical findings (31.6%) and confirmed with biopsy (68.4%). Table 25 demonstrates the clinical performance of the a-GliaPep® IgG assay.

Table 25 Clinical Study Results of a-GliaPep® IgG

		Celiac Disease
		Positive	Negative	Total
α-Gliatest® IgG(Cut-off 50 AU/mL)	Positive	95	22	117
	Negative	10	126	136
	Total	105	148	253

Sensitivity = 90.5% (95% C.1. 83.2% - 95.3%) Specificity = 85.1% (95% C.I. 78.4% - 90.4%)

For the a-GliaPep IgG assay, 145 healthy blood donor samples were also tested, of which 13 samples (9.0%) tested positive.

{16}------------------------------------------------

11.4 Expected Results

The expected result in the normal population is negative. However, the incidence of celiac disease in the normal population is about 1%. Some apparently healthy individuals may test positive for the anti-gliadin antibodies (AGA).

12 Conclusion

The submitted material in this 510(k) Premarket Notification is sufficient to support a substantial equivalence decision with the legally marketed predicate devices.

{17}------------------------------------------------

Image /page/17/Picture/0 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized depiction of a human figure in profile, with three overlapping faces suggesting a sense of community and support. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" is arranged in a circular pattern around the figure, emphasizing the department's role within the United States government. The logo is simple, yet conveys a sense of care and service.

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-002

DEC 1 4 2012

Grifols USA, LLC C/O Ms. Catherine L. Wong Director, Regulatory Affairs 2410 Lillyvale Avenue Los Angeles. CA 90032

Re: K113377

Trade/Device Name: α-Gliatest® IgA, α-Gliatest® IgG, α-GliaPep® IgA, α-GliaPep® IgG Regulation Number: 21 CFR §866.5750

Regulation Name: Radioallergosorbent (RAST) Immunological Test System Regulatory Class: Class II

Product Code: MST

Dated: November 27, 2012

Received: November 28, 2012

Dear Ms. Wong:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 tó 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical

{18}------------------------------------------------

Page 2 - Ms. Catherine L. Wong

device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.

Sincerely yours,

Reena Philip -S

for Maria M. Chan, Ph.D.

Director

Division of Immunology and Hematology Devices Office of In Vitro Diagnostics and Radiological Health (OIR)

Center for Devices and Radiological Health

{19}------------------------------------------------

Indication for Use Statement for α-Gliatest® IgA 1.

510(k) Number (if known): K113377

Device Name: α-Gliatest® IgA

Indication for Use:

The a-Gliatest IgA is intended for the semi-quantitative determination of IgA antibodies directed against gliadin in human serum. The assay is an aid in the diagnosis of celiac disease and should be used in conjunction with other serological tests and clinical findings.

Prescription Use _ X (21 CFR Part 801 Subpart D) And/Or

Over the Counter Use (21 CFR Part 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE; CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)

NZP misar Pampoic

Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety

510(k) K113377

{20}------------------------------------------------

Indication for Use Statement for a-Gliatest® IgG 2.

510(k) Number (if known): K113377

Device Name: α-Gliatest ® IgG

Indication for Use:

Prescription Use X (21 CFR Part 801 Subpart D) And/Or

Over the Counter Use (21 CFR Part 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE; CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)

NZP Nisar Pampori

Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety

510(k) K113377

{21}------------------------------------------------

Indication for Use Statement for α-GliaPep® IgA 3.

510(k) Number (if known): K113377

Device Name: α-GliaPep ® IgA

Indication for Use:

Prescription Use _ X (21 CFR Part 801 Subpart D) And/Or

Over the Counter Use _ (21 CFR Part 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE; CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)

NZGnisar Painpori

Office of In Vitro Diagnostic Device Evaluation and Safety

510(k) K113377

{22}------------------------------------------------

Indication for Use Statement for x-GliaPep® IgG 4.

510(k) Number (if known): K113377

Device Name: α-GliaPep® IgG

Indication for Use:

Prescription Use _ X (21 CFR Part 801 Subpart D) And/Or

Over the Counter Use (21 CFR Part 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE; CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)

NZ-P. Nisar Pampori

Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety

510(k) K113377

Regulation Number and Section

§ 866.5750 Radioallergosorbent (RAST) immunological test system.

(a)
Identification. A radioallergosorbent immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the allergen antibodies (antibodies which cause an allergic reaction) specific for a given allergen. Measurement of specific allergen antibodies may aid in the diagnosis of asthma, allergies, and other pulmonary disorders.(b)
Classification. Class II (special controls). The device, when intended to detect any of the allergens included in Table 1 in this paragraph, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 866.9. Table 1—Class II Exempt Allergens Under § 866.5750—Radioallergosorbent (RAST) Immunological Test Systems
Allergen code Allergen product Source (taxonomical name) Grass Pollens g1 Sweet vernal grass Anthoxanthum odoratum. g3 Cocksfoot grass, Orchard grass Dactylis glomerata. g4 Meadow fescue Festuca elatior. g5 Rye-grass (perennial rye grass) Lolium perenne. g7 Common reed (common reed grass) Phragmites communis. g8 Meadow grass, Kentucky blue (June grass) Poa pratensis. g9 Redtop, Bentgrass Agrostis stolonifera ,Agrostis gigantea (Agrostis alba ). g11 Brome grass Bromus inermis. g12 Cultivated rye (cultivated rye grass) Secale cereale. g13 Velvet grass Holcus lanatus. g14 Cultivated oat (cultivated oat grass) Avena sativa. g15 Cultivated wheat (cultivated wheat grass) Triticum aestivum (Triticum spp.). g16 Meadow foxtail (meadow foxtail grass) Alopecurus pratensis. g17 Bahia grass Paspalum notatum. g24 Wheat grass, Western Agropyron smithii (Elymus smithii ). g30 Bluegrass, annual Poa annua. g70 Wild rye grass Elymus triticoides Elymus condensatus. g71 Canary grass Phalaris arundinacea. g201 Barley, cultivated Hordeum vulgare. g202 Maize, corn (cultivated corn) Zea mays. g203 Salt grass Distichlis spicata. g204 False oat-grass Arrhenatherum elatius. g216 Cyn d 1 Cynodon dactylon. g701 Phl p 1.0102, Phl p 5.0101 Phleum pratense. g702 Phl p 7.0101 Phleum pratense. g703 Phl p 12.0101 Phleum pratense. Weed Pollens w2 Western ragweed Ambrosia psilostachya. w4 False ragweed Ambrosia acanthicarpa (Franseria acanthicarpa ). w5 Wormwood Artemisia absinthium Artemisia annua. w6 Mugwort Artemisia vulgaris. w7 Marguerite, ox-eye daisy Chrysanthemum leucanthemum. w8 Dandelion Taraxacum vulgare ,Taraxacum officinale. w9 Plantain (English), Ribwort Plantago lanceolata. w10 Goosefoot, lamb's quarters Chenopodium album. w11 Saltwort (prickly), Russian thistle Salsola kali (Salsola pestifer ). w12 Goldenrod Solidago virgaurea (Solidago spp.). w13 Cocklebur, common Xanthium commune. w14 Common pigweed (rough pigweed) Amaranthus retroflexus. w15 Scale, Lenscale Atriplex lentiformis. w16 Rough marsh elder Iva ciliate ,Iva annua. w17 Firebush (Kochia) Kochia scoparia. w18 Sheep sorrel Rumex acetosella. w19 Wall pellitory Parietaria officinalis. w20 Nettle (Common stinging nettle) Urtica dioica. w21 Wall pellitory Parietaria judaica. w22 Japanese hop (careless weed) Humulus japonicas (Humulus scandens ). w23 Yellow dock, Yellow dockweed Rumex crispus. w24 Spiny pigweed Amaranthus spinosus. w27 Carnation Dianthus spp. w28 Rose Rosa rugosa. w33 Clover Trifolium pratense. w35 Mexican tea Chenopodium ambrosioides. w36 Rabbit bush Ambrosia deltoidea (Franseria deltoides ). w37 Salt bush, annual Atriplex wrightii. w39 Water hemp, Western Amaranthus rudis (Acnida tamariscina ). w41 Burrobrush Hymenoclea salsola. w42 Poverty weed Baccharis neglecta. w43 Common sagebrush Artemisia tridentata. w45 Alfalfa Medicago sativa. w46 Dog fennel Eupatorium capillifolium. w53 Geranium Geranium spp. w67 Groundsel bush Baccharis halimifolia. w69 Iodine bush Allenrolfea occidentalis. w70 Ragweed, slender Ambrosia confertiflora. w75 Wing scale (wingscale) Atriplex canescens. w82 Careless weed Amaranthus palmeri ,Amaranthus hybridus. w90 Japanese hop Humulus japonicas (Humulus scandens ). w203 Rape (rape pollen) Brassica napus. w204 Sunflower Helianthus annuus. w206 Camomile Matricaria chamomilla. w207 Lupin Lupinus spp. w210 Sugar-beet Beta vulgaris. w211 Par j 2.0101 Parietaria judaica. w231 Art v 1 Artemisia vulgaris (Mugwort). w232 Sal k 1 Salsola kali. w233 Art v 3 Artemisa vulgaris (LTP, Mugwort). w234 Pla l 1 Plantago lanceolata. w235 Che a 1.0101 Chenopodium album. w236 Mer a 1.0101 Mercurialis annua. a753 Art v 1 Artemisia vulgaris (Mugwort weed). Tree Pollens t1 Box-elder (Maple) Acer negundo ,Acer saccharum. t2 Gray alder, speckled alder (alder) Alnus incana. t4 Hazel, hazelnut Corylus avellana ,Corylus americana. t5 American beech (beech) Fagus grandifolia (Fagus americana ). t6 Mountain juniper, Mountain cedar Juniperus ashei (Juniperus sabinoides ). t8 Elm Ulmus americana. t9 Olive Olea europaea. t10 Walnut Juglans californica ,Juglans nigra. t11 Maple leaf sycamore, London plane, Plane tree Platanus acerifolia. t61 Sycamore Platanus occidentalis. t12 Willow Salix caprea ,Salix nigra. t14 Cottonwood (Eastern Cottonwood/Black Cottonwood) Populus deltoides. t15 White ash Fraxinus americana. t16 White pine Pinus strobus. t18 Eucalyptus, gum-tree Eucalyptus globulus (Eucalyptus spp.). t19/t26 Acacia Acacia longifolia (Acacia spp.). t20 Mesquite Prosopis glandulosa/ Prosopis juliflora. t21 Melaleuca, cajeput tree Melaleuca quinquenervia (Melaleuca leucadendron ). t22 Pecan, hickory Carya illinoinensis (Carya pecan ). t23 Italian/Mediterranean/funeral cypress Cupressus sempervirens. t24 Japanese cypress Chamaecyparis obtusa (Chamaecyparis spp.). t25 Ash Fraxinus excelsior. t27 Maple, red Acer rubrum. t29 Acacia Acacia spp. t30 Birch, white Betula populifolia. t32 Willow, black Salix nigra. t33 Ash, Arizona Fraxinus velutina. t35 Cedar, salt Tamarix gallica. t37 Bald cypress (white bald cypress) Taxodium distichum. t38 Elm, Chinese/Siberian Ulmus pumila. t40 Hazelnut tree Corylus americana. t41 White hickory Carya alba (Carya tomentosa ). t42 Oak, red Quercus rubra. t43 Loblolly pine Pinus taeda. t44 Hackberry Celtis occidentalis. t45 Cedar elm Ulmus crassifolia. t47 Juniper, one seed Juniperus monosperma. t48 Pine, lodgepole Pinus contorta. t49 Pine, ponderosa Pinus ponderosa. t50 Beech, European Fagus sylvatica. t51 Tree of Heaven Ailanthus altissima. t52 Western white pine Pinus monticola. t54 Russian olive Elaeagnus angustifolia. t55 Scotch broom Cytisus scoparius. t56 Bayberry Myrica cerifera. t57 Red cedar Juniperus virginiana. t60 Western juniper Juniperus occidentalis. t61 Sycamore Platanus occidentalis. t70 Mulberry (white mulberry) Morus alba. t71 Red mulberry Morus rubra. t72 Queen palm Arecastrum romanzoffiamon. t73 Australian pine Casuarina equisetifolia. t77 Oak mix (red, white, black) Quercus spp. t80 Japanese cypress Chamaecyparis obtusa. t81 Japanese alder Alnus japonica. t83 Mango tree Mangifera indica. t90 Walnut, black Juglans nigra. t96 Poplar, white (poplar) Populus alba. t103/t218 Virginia live oak (live oak) Quercus virginiana. t105 Pepper tree Schinus molle. t110 Orange tree Citrus sinensis. t201 Spruce, Norway spruce Picea abies (Picea excelsa ). t202 Alder, smooth Alnus incana spp.Rugosa (Alnus rugosa ). t203 Horse chestnut Aesculus hippocastanum. t205 Elder Sambucus nigra. t206 Chestnut Castanea sativa. t207 Douglas fir Pseudotsuga menziesii (Pseudotsuga taxifolia ). t208 Linden Tilia cordata. t209 Horn beam Carpinus betulus. t210 Privet Ligustrum vulgare. t211 Sweet gum Liquidambar styraciflua. t212 Cedar Libocedrus decurrens. t213 Pine Pinus radiata. t214 Date palm Phoenix canariensis. t215 Lilac Syringa vulgaris. t217 Pepper tree Schinus molle. t217 Red alder Alnus rubra. t218 Virginia live oak Quercus virginiana. t218 Bayberry (bayberry/sweet gale) Myrica gale. t219 Palo verde Cercidium floridum. t219 Red cedar Juniperus virginiana. t220 Bet v 4 Betula verrucosa (Birch). t221 Bet v 2.0101, Bet v 4 Betula verrucosa (Birch). t222 Cypress (Arizona cypress) Cupressus arizonica. t223 Oil palm Elaeis guineensis. t224 Ole e 1 Olea europaea. t225 Bet v 6 Betula verrucosa (Birch). t226 Cup a 1 Cupressus arizonica. t227 Ole e 7 Olea Europaea. t228 Aspen, quaking Populus tremuloides. t229 Eastern hemlock Tsuga canadensis. t230 Redwood (sequoia) Sequoia sempervirens. t232 Pussy willow Salix discolor. t240 Ole e 9.0101 Olea Europaea. t241 Pla a 1.0101 Platanus acerifolia. t242 Pla a 2 Platanus acerifolia. t243 Pla a 3.0101 Platanus acerifolia. t244 Cor a 1.0103 Corylus avellana. t245 Aln g 1.0101 Alnus glutinosa. t246 Cry j 1 Cryptomeria japonica. t280 Locust tree Robinia pseudoacacia. t401 Brazilian peppertree Schinus terebinthifolius. t402 Mastic tree Pistacia lentiscus. t404 Tree of heaven Ailanthus altissima. t406 Date palm Phoenix dactylifera. a482 Ole e 1 Olea europaea (Olive Oil). Mites d207 Blo t 5.0101 Blomia tropicalis. d208 Lep d 2.0101 Lepidoglyphus destructor. Microorganisms, Molds, Yeast m1 Penicillium chrysogenum (Penicillium notatum ) Penicillium chrysogenum (Penicillium notatum ). m2 Cladosporium herbarum (Hormodendrum ) Cladosporium herbarum (Hormodendrum ). m3 Aspergillus fumigatus Aspergillus fumigatus. m4 Mucor racemosus Mucor racemosus. m5 Candida albicans Candida albicans. m7 Botrytis cinerea Botrytis cinerea. m8 Drechslera halodes (Setomelanomma rostrata, Helminthosporium halodes, Helminthosporium interseminatum ) Drechslera halodes (Setomelanomma rostrata, Helminthosporium halodes. m9 Fusarium moniliforme (Fusarium proliferatum ) Fusarium moniliforme (Fusarium proliferatum ). m10 Stemphylium botryosum Stemphylium herbarum (Stemphylium botryosum ). m11 Rhizopus nigricans Rhizopus nigricans. m12 Aureobasidium pullulans Aureobasidium pullulans. m13 Phoma betae Phoma betae. m14 Epicoccum purpurascens Epicoccum purpurascens (Epicoccum nigrum ). m15 Trichoderma viride Trichoderma viride. m16 Curvularia lunata Curvularia lunata ,Curvularia specifera ([K923044](https://510k.innolitics.com/search/[K923044](https://510k.innolitics.com/search/K923044)) ). m17 Cladosporium fulvum Cladosporium fulvum. m18 Fusarium culmorum Fusarium culmorum. m19 Aspergillus versicolor Aspergillus versicolor. m20 Mucor mucedo Mucor mucedo. m21 Aspergillus clavatus Aspergillus clavatus. m22 Micropolyspora faeni Saccharopolyspora rectivirgula (Micropolyspora faeni ). m23 Thermoactinomyces vulgaris Thermoactinomyces vulgaris. m24 Stachybotrys atra Stachybotrys chartarum (Stachybotrys atra ). m24 Paecilomyces spp Paecilomyces spp. m25 Aspergillus versicolor Aspergillus versicolor. m25 Penicillium brevicompactum Penicillium brevicompactum. m26 Cladosporium cladosporioides Cladosporium cladosporioides. m26 Penicillium citrinum Penicillium citrinum. m27 Penicillium spp Penicillium spp. m29 Aspergillus repens Aspergillus repens. m30 Penicillium roqueforti Penicillium roqueforti. m32 Cladosporium cladosporioides Cladosporium cladosporioides. m34 Serpula lacrymans Serpula lacrymans. m36 Aspergillus terreus Aspergillus terreus. m37 Trichophyton mentagrophytes Trichophyton mentagrophytes. m40 Aspergillus amstelodami Aspergillus amstelodami. m43 Saccharomyces Carlsberg Saccharomyces carlsbergensis. m44 Saccharomyces cerevisiae Saccharomyces cerevisiae. m45 Hormodendrum hordei Hormodendrum hordei. m46 Bipolaris spicifera Bipolaris spicifera. m47 Aspergillus nidulans Aspergillus nidulans. m48 Aspergillus oryzae Aspergillus oryzae. m49 Fusarium oxysporum Fusarium oxysporum. m50 Micropolyspora faeni Saccharopolyspora rectivirgula (Micropolyspora faeni ). m51 Thermoactinomyces vulgaris Thermoactinomyces vulgaris. m53 Microspora canis Microsporum canis (Microspora canis ). m54 Aspergillus flavus Aspergillus flavus. m63 Helminthosporium intersemin Helminthosporium intersemin. m66 Mucor plumbeus Mucor plumbeus. m67 Mycogone Mycogone perniciosa. m68 Nigrospora oryzae Nigrospora oryzae. m69 Rhodotorula Rhodotorula rubra (Rhodotorula mucilaginosa ). m70 Malassezia furfur (Pityrosporum orbiculare ) Malassezia furfur (Pityrosporum orbiculare ). m71 Spondylocladium Spondylocladium spp. m72 Epidermophyton Epidermophyton floccosum. m73 Epicoccum nigrum Epicoccum purpurascens (Epicoccum nigrum ). m80 Staphylococcal enterotoxin A (Sta a SEA ) Staphylococcus aureus. m80 Helminthosporium spp Helminthosporium spp. m81 Staphylococcal enterotoxin B (Sta a SEB ) Staphylococcus aureus. m88 Stemphylium solani Stemphylium solani. m93 Gliocladium fimbriatum Gliocladium fimbriatum. m94 Phycomyces blakesleeanus Phycomyces blakesleeanus. m201 Tilletia tritici (Ustilago nuda, Ustilago tritici ) (Barley smut) Tilletia tritici (Ustilago nuda, Ustilago tritici ). m202 Acremonium kiliense (Cephalosporium acremonium ) Acremonium kiliense (Cephalosporium acremonium ). m203 Trichosporon pullulans Trichosporon pullulans. m204 Ulocladium chartarum Ulocladium chartarum. m205 Trichophyton rubrum Trichophyton rubrum. m207 Aspergillus niger Aspergillus niger. m208 Chaetomium globosum Chaetomium globosum. m209 Penicillium frequentans Penicillium glabrum (Penicillium frequentans ). m209 Stachybotrys chartarum Stachybotrys chartarum (Stachybotrys atra ). m210 Trichophyton mentagrophytes var. goetzii Trichophyton mentagrophytes var. goetzii. m211 Trichophyton mentagrophytes var. interdigitale Trichophyton mentagrophytes var. interdigitale. m211 Oat smut Ustilago avenae. m212 Micropolyspora faeni Saccharopolyspora rectivirgula (Micropolyspora faeni ). m212 Geotrichum candidum Geotrichum candidum. m213 Bermuda grass smut Ustilago cynodontis. m214 Johnson grass smut Sphacelotheca cruenta. m215 Corn smut Ustilago maydis. m218 Asp f 1.0101 Aspergillus fumigatus. a3050 Asp r 1 Aspergillus restrictus. m219 Asp f 2 Aspergillus fumigatus. m220 Asp f 3.0101 Aspergillus fumigatus. m221 Asp f 4 Aspergillus fumigatus. m222 Asp f 6.0101 Aspergillus fumigatus. m223 Staphylococcal enterotoxin C (Sta a SEC ) Staphylococcus aureus. m224 Staphylococcal enterotoxin D (Sta a SED ) Staphylococcus aureus. m226 Staphylococcal enterotoxin TSST (Sta a TSST ) Staphylococcus aureus. m227 Malassezia spp. (Pityrosporum spp.) Malassezia spp. (Pityrosporum spp.). m228 Aspergillus flavus. m229 Alt a 1.0101 Alternaria alternata (Alternaria tenuis ). m230 Alt a 6.0101 Alternaria alternata (Alternaria tenuis ). m231 Cla h 8.0101 Cladosporium herbarum (Hormodendrum ). m300 Eurotium spp Eurotium spp. m304 Aspergillus oryzae Aspergillus oryzae. m305 Penicillium brevicompactum Penicillium brevicompactum. m309 Aspergillus terreus Aspergillus terreus. m310 Aspergillus nidulans Aspergillus nidulans. m311 Aspergillus flavus Aspergillus flavus. m312 Aspergillus clavatus Aspergillus clavatus. Epidermal & Animal e6 Guinea pig epithelium Cavia porcellus. e7 Pigeon droppings Columba palumbus ,Columba livia. e25 Chicken serum Gallus domesticus (Gallus gallus domesticus; Gallus spp.). e26 Parrot serum Psittacoidea spp. e62 Camel Camelus dromedaries. e70 Goose feathers Anser anser. e71 Mouse epithelium Mus musculus (Mus spp.). e73 Rat epithelium Rattus norvegicus. e74 Rat urine proteins Rattus norvegicus ,Rattus rattus. e75 Rat serum proteins Rattus norvegicus ,Rattus rattus. e76 Mouse serum proteins Mus musculus (Mus spp.). e77 Budgerigar droppings Melopsittacus undulatus. e78 Budgerigar feathers Melopsittacus undulatus. e79 Budgerigar serum proteins Melopsittacus undulatus. e80 Goat epithelium Capra hircus. e81 Sheep epithelium Ovis aries (Ovis spp.). e82 Rabbit epithelium Oryctolagus cuniculus (Oryctolagus spp.). e83 Swine epithelium Sus scrofa (Sus scrofa domesticus; Sus spp.). e84 Hamster epithelium Cricetus cricetus, Mesocricetus auratus, and Phodopus sungorus. e85 Chicken feathers Gallus domesticus (Gallus gallus domesticus; Gallus spp.). e86 Duck feathers Anas platyrhynchos. e87 Rat epithelium, serum proteins, and urine proteins Rattus norvegicus Rattus rattus. e88 Mouse epithelium, serum proteins, and urine proteins (mouse) Mus musculus (Mus spp.). e89 Turkey feathers Meleagris gallopavo. e90 Budgerigar serum proteins, feathers, and droppings Melopsittacus undulatus. e91 Pigeon serum proteins, feathers, and droppings Streptopelia roseogrisea ,Psittacidae spp. e92 Parrot serum proteins, feathers, and droppings Ara spp. e93 Pigeon serum proteins Streptopelia roseogrisea. e94 Fel d 1.0101 Felis domesticus. a345 Fel d 1 Felis domesticus. e98 Parrot droppings Psittacoidea spp. e101 Can f 1.0101 Canis familiaris (Canis domesticus ). a174 Can f 1 Canis familiaris (Canis domesticus ). e102 Can f 2.0101 Canis familiaris (Canis domesticus ). e196 Parakeet feathers Nymphicus hollandicus. e197 Parakeet droppings Nymphicus hollandicus. e198 Parakeet serum Nymphicus hollandicus. e199 Canary bird serum Serinus canarius. e200 Canary bird droppings Serinus canarius. e201 Canary bird feathers (Canary feathers) Serinus canarius. e202 Reindeer epithelium Rangifer tarandus. e203 Mink epithelium Mustela spp. e204 Bos d 6 Bos domesticus (Bos taurus; Bos spp.). e205 Horse, serum proteins Equus caballus (Equus spp.). e206 Rabbit, serum proteins Oryctolagus cuniculus (Oryctolagus spp.). e208 Chinchilla epithelium Chinchilla laniger. e209 Gerbil epithelium Meriones unguiculatus. e210 Fox epithelium Vulpes vulpes. e211 Rabbit, urine proteins Oryctolagus cuniculus (Oryctolagus spp.). e212 Swine, urine proteins Sus scrofa (Sus scrofa domesticus; Sus spp.). e213 Parrot feathers Ara spp. e214 Finch feathers Lonchura domestica. e215 Pigeon feathers Streptopelia roseogrisea (Streptopelia spp.),Columbia spp. e216 Deer epithelium Dama dama. e217 Ferret epithelium Mustela putorius. e218 Chicken droppings Gallus domesticus (Gallus gallus domesticus; Gallus spp.). e219 Chicken, serum proteins Gallus domesticus (Gallus gallus domesticus; Gallus spp.). e220 Fel d 2, Cat serum albumin Felis domesticus. e221 Can f 3 Canis familiaris (Canis domesticus ) (Dog serum albumin ). e222 Swine serum albumin (Sus s PSA) Sus scrofa (Sus scrofa domesticus; Sus spp.). e225 Lovebird feathers Psittacoidea agapomis. e226 Can f 5.0101 Canis familiaris. e227 Equ c 1.0101 Equus caballus. e228 Fel d 4.0101 Felis domesticus. e230 Equ c 3 Equus caballus. e231 Mus m 1 Mus musculus. Food f9 Rice Oryza sativa. f12 Pea (green pea) Pisum sativum. f15 White bean Phaseolus vulgaris. f19 Cayenne pepper Capsicum frutescens (Capsicum annum ). f21 Sugar cane Saccharum officinarum. f22 Raspberry Rubus idaeus. f26 Pork Sus scrofa (Sus scrofa domesticus; Sus spp.). f29 Watermelon Citrullus lanatus (Citrullus vulgaris ). f31 Carrot Daucus carota. f32 Oyster mushroom Pleurotus ostreatus. f33 Orange Citrus sinensis. f35 Potato Solanum tuberosum. f43 Mother's milk Homo sapiens. f44 Strawberry Fragaria vesca (Fragaria spp.). f45 Yeast, baker's Saccharomyces cerevisiae. f46 Pepper, Red Capsicum annuum. f47 Garlic Allium sativum. f48 Onion Allium cepa. f49 Apple Malus x domestica (Malus spp.). f51 Bamboo shoot Phyllostachys pubescens. f52 Cacao/chocolate Theobroma cacao. f54 Sweet potato Ipomoea batatas. f55 Common millet Panicum miliaceum. f56 Foxtail millet Setaria italica. f57 Japanese millet Echinochloa crus-galli. f58 Pacific squid Todarodes pacificus. f59 Octopus Octopus vulgaris (Octopus spp.). f63 Kefir NA. f67 Parmesan cheese NA. f81 Cheese, cheddar type NA. f82 Cheese, mold type NA. f83 Chicken Gallus domesticus (Gallus gallus domesticus; Gallus spp.). f86 Parsley Petroselinum crispum. f87 Melon Cucumis melo Cucumis melo + Citrullus lanatus. f88 Mutton (lamb) Ovis aries (Ovis spp.). f90 Malt Hordeum vulgare. f92 Banana Musa spp. f93 Cacao Theobroma cacao. f94 Pear Pyrus communis (Pyrus spp.). f97 Yam Dioscorea spp.Dioscorea opposita. f97 Chamomile tea Matricaria chamomilla. f98 Gliadin Triticum aestivum (Triticum spp.). f102 Cantaloupe Cucumis melo var. cantalupensis. f105 Chocolate Theobroma cacao. f109 Cottonseed Gossypium hirsutum. f110 Giant radish Raphanus sativus. f118 Zucchini Cucurbita pepo. f119 Radish Raphanus sativus. f120 Venison Capreolus capeolus. f121 Pinto bean Phaseolus vulgaris. f122 Cheese, American NA. f127 Black-eyed pea Vigna unguiculata. f131 Black Olive Olea europaea. f136 Red beet Beta vulgaris var. conditiva. f139 Goat's Cheese Capra aegagrus. f140 Bran NA. f141 Corn (vegetables) Zea mays. f152 Green bell pepper Capsicum annuum. f155 Brewer's yeast Saccharomyces carlsbergensis. f157 Duck Anas domesticus. f158 Goose Anser anser. f160 Camembert cheese NA. f162 Nectarine Prunus persica var. nucipersica. f163 Kohlrabi Brassica oleracea var. gongylodes. f65 Perch f166 Leek Allium porrum. f170 Cheese (Switzerland) (Swiss cheese) NA. f174 Fig Ficus carica. f177 Cranberry Vaccinium macrocarpon. f179 Raisin Vitis spp. f182 Lima bean Phaseolus lunatus. f198 Flaxseed (bruised grain) Linum usitatissimum. f199 Untreated native milk Bos domesticus (Bos taurus; Bos spp.). f208 Lemon Citrus limon. f209 Grapefruit Citrus paradisi. f210 Pineapple Ananas comosus. f211 Blackberry Rubus fruticosus. f212 Mushroom (champignon) Agaricus hortensis (Agaricus spp.). f213 Rabbit Oryctolagus cuniculus (Oryctolagus spp.). f214 Spinach Spinacia oleracea. f215 Lettuce Lactuca sativa. f216 Cabbage Brassica oleracea var. capitata. f217 Brussels sprouts Brassica oleracea var. gem. f218 Paprika, sweet pepper Capsicum annuum. f219 Fennel seed Foeniculum vulgare. f219 Sage Salvia officinalis. f220 Cinnamon Cinnamomum spp. f221 Coffee Coffea spp. f222 Tea Camellia sinensis. f223 Green olive Olea europaea. f225 Summer squash, pumpkin Cucurbita pepo. f225 Pumpkin Cucurbita maxima. f226 Pumpkin seed Cucurbita pepo. f227 Sugar-beet seed Beta vulgaris. f229 Safflower Seed Carthamus tinctorius. f231 Milk, boiled Bos domesticus (Bos taurus; Bos spp.). f234 Vanilla Vanilla planifolia. f237 Apricot Prunus armeniaca. f241 Gouda cheese NA. f242 Cherry Prunus avium. f244 Cucumber Cucumis sativus. f246 Guar, guar gum Cyamopsis tetragonoloba. f247 Honey NA. f248 Rosemary Rosmarinus officinalis. f254 Plaice Pleuronectes platessa. f255 Plum Prunus domestica ,Prunus americana. f258 Squid Loligo spp. f259 Grape Vitis vinifera (Vitis spp.). f260 Broccoli Brassica oleracea var. italica (Brassica oleracea var. cultivar ). f261 Asparagus Asparagus officinalis. f262 Aubergine, eggplant Solanum melongena. f263 Green pepper Piper nigrum ,Capsicum annuum. f264 Eel Anguilla anguilla. f265 Caraway Carum carvi. f265 Cumin Cuminum cyminum. f266 Mace Myristica fragrans. f267 Cardamon Elettaria cardamomum. f268 Clove Syzygium aromaticum. f269 Basil Ocimum basilicum. f270 Ginger Zingiber officinale. f271 Anise Pimpinella anisum. f272 Tarragon Artemisia dracunculus. f273 Thyme Thymus vulgaris. f274 Marjoram Origanum majorana. f275 Lovage Levisticum officinale. f276 Fennel, fresh Foeniculum vulgare. f277 Dill Anethum graveolens. f278 Bay leaf Laurus nobilis. f279 Chili pepper Capsicum frutescens. f280 Black pepper Piper nigrum. f281 Curry (Santa Maria) NA. f282 Nutmeg Myristica fragrans. f283 Oregano Origanum vulgare. f284 Turkey meat Meleagris gallopavo. f285 Elk/moose meat Alces spp. f286 Mare's milk Equus caballus (Equus spp.). f287 Red kidney bean Phaseolus vulgaris. f288 Blueberry Vaccinium myrtillus (Vaccinium spp.). f289 Date Phoenix dactylifera. f291 Cauliflower Brassica oleracea var. botrytis. f292 Guava Psidium guajava. f293 Papaya Carica papaya. f294 Passion fruit, Maracuja Passiflora edulis (Passiflora spp.). f295 Carambola Averrhoa carambola. f296 Carob Ceratonia siliqua. f297 Gum Arabic Acacia senegal (Acacia spp.). f298 Tragacanth Astragalus spp. f299 Sweet chestnut (chestnut) Castanea sativa. f300 Pinto bean Phaseolus spp. f301 Persimmon (kaki fruit, sharon) Diospyros kaki. f302 Mandarin (tangerine, clementine, satsumas) Citrus reticulata. f305 Fenugreek Trigonella foenum-graecum. f306 Lime Citrus aurantifolia. f307 Hake Merluccius merluccius. f308 Sardine (pilchard) Sardina pilchardus. f310 Blue vetch Lathyrus sativus. f311 Megrim Lepidorhombus whiffiagonis. f315 Green bean Phaseolus vulgaris. f316 Rape seed Brassica napus. f317 Coriander Coriandrum sativum. f318 Jack fruit Artocarpus heterophyllus. f319 Beetroot Beta vulgaris. f320 Crayfish Astacus astacus. f321 Horse meat Equus caballus (Equus spp.). f322 Red currant Ribes sylvestre. f324 Hop (fruit cone) Humulus lupulus. f325 Saffron Colchicum autumnale. f328 Fig Ficus carica. f329 Watermelon Citrullus lanatus. f330 Rose hip Rosa spp. f331 Saffron Crocus sativus. f332 Mint Mentha piperita. f333 Linseed Linum usitatissimum. f336 Jujube Ziziphus jujuba. f336 Wine vinegar Vitis vinifera (Vitis spp.). f337 Sole Solea solea. f337 English sole Parophrys vetulus. f338 Wine, white Vitis vinifera (Vitis spp.). f339 Allspice Pimenta dioica. f339 Wine, red Vitis vinifera (Vitis spp.). f341 Cranberry Vaccinium oxycoccus ,Vaccinium macrocarpon. f342 Olive (black, fresh) Olea europaea. f343 Raspberry Rubus idaeus. f344 Sage Salvia officinalis. f346 Chives Allium schoenoprasum. f347 Quinoa Chenopodium quinoa. f348 Litchi Litchi chinensis. f349 Chum salmon roe Oncorhynchus keta. f358 Artichoke Cynara scolymus. f360 Yogurt NA. f368 Black bass Micropterus dolomieu (Micropterus dolomieui ). f374 Karaya gum Sterculia urens. f375 Horseradish Armoracia rusticana. f377 Maple syrup NA. f379 Okra Abelmoschus esculentus. f382 Beet, sugar Beta vulgaris var. altissima. f401 Loquat Eriobotrya japonica. f402 Fig Ficus carica. f403 Brewer's yeast Saccharomyces cerevisiae. f405 Mint Mentha spp. f406 Arugula Eruca vesicaria. House Dust h1 Greer Labs., Inc NA. h2 Hollister-Stier Labs NA. h6 Japan NA. Venoms & Insects i7 Midge Chironomus yoshimatsui. i8 Moth Bombyx mori ,Heterocera spp. i47 Water flea Daphnia spp. i49 Deer fly Chrysops spp. i51 Black ant Camponotus pennsylvanicus. i54 Flea mix (dog/cat), common flea Ctenocephalides spp. i71 Mosquito Aedes communis ,Aedes spp.and Culex spp. i72 Green nimitti Cladotanytarsus lewisi. i73 Blood worm Chironomus thummi ,Chironomusri parius ,Chironomus spp. i75 European hornet Vespa crabro. i76 Berlin beetle Trogoderma angustum. i77 European paper wasp Polistes dominulus. i78 Fly Musca domestica. i80 Bumblebee Bombus pennsylvanicus. i201 Horse bot fly Gasterophilus intestinalis. i202 Grain weevil Sitophilus granarius. i203 Mediterranean flour moth Ephestia kuehniella (Anagasta kuehniella ). i204 Horse fly Tabanus spp. i205 Bumblebee Bombus terrestris. i208 Api m 1.0101 Apis mellifera. a45 Api m 1 Apis mellifera. i209 Ves v 5.0101 Vespula vulgaris. a670 Ves v 5 Vespula vulgaris. i210 Pol d 5.0101 Polistes dominulus. i211 Ves v 1.0101 Vespula vulgaris. i213 Api m 4 Apis mellifera. i214 Api m 2 Apis mellifera. i215 Api m 3 Apis mellifera. i216 Api m 5 Apis mellifera. i217 Api m 10 Apis mellifera. i220 Bla g 1.0101 Blattella germanica. i221 Bla g 2.0101 Blattella germanica. i222 Bla g 5.0101 Blattella germanica. i223 Bla g 7 Blattella germanica. a46 Api m 2 Apis mellifera. Miscellaneous o1 Cotton, crude fibers Gossypium spp. o3 Cotton (treated) Gossypium spp. o70 Seminal fluid Homo sapiens. o71 Staphylococcus aureus Staphylococcus aureus. o72 Pichia pastoris crude extract customer specific Pichia pastoris. o72 Sperm-sediment Homo sapiens. o73 Pichia pastoris crude extr. vector customer specific Pichia pastoris. o74 Pichia pastoris with vector customer specific Pichia pastoris. o201 Tobacco leaf, tobacco dust Nicotiana tabacum. o202 Artemia salina, fish feed Artemia salina. o203 Tetramin, fish feed NA. o207 Daphnia, fish feed Daphnia spp. o211 Mealworm Tenebrio molitor. o212 Streptavidin Streptomyces avidini. o213 MBP (maltose binding protein) Escherichia coli. o214 CCD; MUXF3 from bromelain Ananas comosus. o72 Enterotoxin A (Sta a SEA) Staphylococcus aureus. o73 Enterotoxin B (Sta a SEB) Staphylococcus aureus. Parasites p1 Ascaris Ascaris suum. p2 Echinococcus Echinococcus granulosus. p3 Schistosoma Schistosoma mansoni. p4 Anisakis (Herring Worm) Anisakis simplex (Anisakis spp.). p5 Toxocara canis Toxocara canis. p10 Ani s 3.0101 Anisakis simplex (Anisakis spp.). p11 Ani s 1 Anisakis simplex (Anisakis spp.). Occupational k4 Threshing dust NA. k5 Flax NA. k7 Hay Dust NA. k8 Hop (hops) Humulus lupulus. k12 Grain mill dust NA. k14 Kapok NA. k20 Sheep's wool (treated) (wool) Ovis aries (Ovis spp.). k21 Sheep's wool (Untreated) Ovis aries (Ovis spp.). k23 Straw Dust NA. k33 Oak NA. k70 Green coffee bean Coffea spp. k71 Castor bean Ricinus communis. k72 Ispaghula Plantago psyllium/Plantago ovata. k73 Silk waste NA. k74 Silk Bombyx mori. k75 Isocyanate TDI (Toluene diisocyanate) NA. k76 Isocyanate MDI (Diphenylmethane diisocyanate) NA. k77 Isocyanate HDI (Hexamethylen diisocyanate) NA. k78 Ethylene oxide NA. k79 Phthalic anhydride NA. k80 Formaldehyde/Formalin NA. k81 Ficus Ficus benjamina (Ficus spp.). k83 Cotton seed Gossypium hirsutum. k84 Sunflower seed Helianthus annuus. k85 Chloramin T NA. k86 Trimellitic anhydride, TMA NA. k87 Asp o 21, alpha-amylase Aspergillus oryzae. k89 Orris root Iris florentina. k99 HSA (Human Serum Albumin) (Hom s HSA) Homo sapiens. k201 Car p 1, Papain Carica papaya. k202 Ana c 2, Bromelain Ananas comosus. k204 Maxatase Bacillus licheniformis. k205 Alcalase Bacillus spp. k206 Savinase, Protease 1 (Bac l Subtilisin) Bacillus spp. k208 Gal d 4, Lysozyme Gallus domesticus (Gallus gallus domesticus; Gallus spp.). k209 Hexahydrophtalic anhydrid NA. k210 Maleic anhydride NA. k211 Methyltetrahydrophtalic anhydrid NA. k212 Abachi wood dust Triplochiton scleroxylon. k213 Pepsin (Sus s Pepsin) Sus scrofa (Sus scrofa domesticus; Sus spp.). k213 TCPA NA. k214 Bougainvillea Bougainvillea spp. k225 Horse radish peroxidase (Arm r HRP) Armoracia rusticana. k226 Ascorbate oxidase (Cuc p ascorbate oxidase) Cucurbita pepo. k301 Flour dust Triticum spp. k501 Savinase customer specific Proprietary knowledge of customer. k502 Lipolase customer specific Proprietary knowledge of customer. k503 Termamyl customer specific Proprietary knowledge of customer. k504 Clazinase customer specific Proprietary knowledge of customer.